Menu
Search
|

Menu

Close
X

Audentes Therapeutics Inc BOLD.OQ (NASDAQ Stock Exchange Global Market)

31.84 USD
-- (--)
As of Feb 20
chart
Previous Close 31.84
Open --
Volume --
3m Avg Volume 111,725
Today’s High --
Today’s Low --
52 Week High 41.80
52 Week Low 14.00
Shares Outstanding (mil) 27.78
Market Capitalization (mil) 722.67
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.91 Mean rating from 11 analysts

KEY STATS

Revenue (mm, USD)
FY17
0
FY16
0
FY15
0
EPS (USD)
FY17
-2.581
FY16
-3.009
FY15
-1.259
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.90
Price to Sales (TTM)
vs sector
--
5.77
Price to Book (MRQ)
vs sector
4.46
5.41
Price to Cash Flow (TTM)
vs sector
--
23.42
Total Debt to Equity (MRQ)
vs sector
2.48
16.52
LT Debt to Equity (MRQ)
vs sector
2.39
12.22
Return on Investment (TTM)
vs sector
-57.99
14.43
Return on Equity (TTM)
vs sector
-145.70
16.13

EXECUTIVE LEADERSHIP

Matthew Patterson
President, Chief Executive Officer, Co-Founder, Director, Since
Salary: $441,760.00
Bonus: --
Thomas Schuetz
Co-Founder, Independent Director, Since 2013
Salary: --
Bonus: --
Thomas Soloway
Chief Financial Officer, Senior Vice President, Since 2017
Salary: $360,500.00
Bonus: --
Natalie Holles
Chief Operating Officer, Senior Vice President, Since 2015
Salary: $360,500.00
Bonus: --
David Nagler
Senior Vice President - Human Resources and Corporate Affairs, Since 2015
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

600 California St Fl 17
SAN FRANCISCO   CA   94108-2725

Phone: +1415.6386556

Audentes Therapeutics, Inc. is an early-stage biotechnology company. The Company is focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases caused by single gene defects. The Company has a portfolio of product candidates, including AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM); AT342 for the treatment of Crigler-Najjar Syndrome (Crigler-Najjar); AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT). The Company's subsidiary is Audentes Therapeutics UK Ltd. As of September 30, 2016, the Company had not generated any revenues.

SPONSORED STORIES